Skip to main content
. 2020 Feb 28;9(3):648. doi: 10.3390/jcm9030648

Figure 5.

Figure 5

Survival with most popular first line regimens versus all other therapies within the two time periods. Kaplan-Meier curves of patients who started a first line therapy with either one of the two regimens gemcitabine/nab-paclitaxel and mFOLFIRINOX compared to all other therapies between 2011–2013 (A), 2014–2017 (B), as well as for the whole time period (C).